R

Radiopharm Theranostics Ltd
ASX:RAD

Watchlist Manager
Radiopharm Theranostics Ltd
ASX:RAD
Watchlist
Price: 0.019 AUD -9.52% Market Closed
Market Cap: 52.8m AUD

Radiopharm Theranostics Ltd
Revenue

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Radiopharm Theranostics Ltd
Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Revenue CAGR 3Y CAGR 5Y CAGR 10Y
R
Radiopharm Theranostics Ltd
ASX:RAD
Revenue
AU$3.6m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Opthea Ltd
ASX:OPT
Revenue
$25k
CAGR 3-Years
-35%
CAGR 5-Years
-16%
CAGR 10-Years
-30%
Mesoblast Ltd
ASX:MSB
Revenue
$17.2m
CAGR 3-Years
19%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
CSL Ltd
ASX:CSL
Revenue
$15.6B
CAGR 3-Years
14%
CAGR 5-Years
11%
CAGR 10-Years
11%
Telix Pharmaceuticals Ltd
ASX:TLX
Revenue
AU$507.9m
CAGR 3-Years
306%
CAGR 5-Years
171%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Revenue
AU$26.2m
CAGR 3-Years
18%
CAGR 5-Years
59%
CAGR 10-Years
41%
No Stocks Found

Radiopharm Theranostics Ltd
Glance View

Market Cap
52.8m AUD
Industry
Biotechnology

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-11-25. The firm is a developer of platform of radiopharmaceutical products for both diagnostic and therapeutic uses. The company has a pipeline of four licensed platform technologies, namely Nano- monoclonal antibodies (mAbs) technology, Pivalate, AVb6 Integrin and PSA-mAb. Nano-mAbs technology platform provides Nano-mAbs, which are made using genetically engineered camelid derived single domain antibodies (sdAb), that are labelled with radioisotopes to diagnose and treat specific cancers expressing HER-2, TROP-2, PD-L1 and PTK7 receptors. Pivalate is an F-FPIA radiotracer, and its technology is based on a short chain carbohydrate. Its clinical program includes five Phase I clinical trials, five Phase II clinical trials, and two Phase I clinical trials targeting a various cancer, including breast, lung, kidney, head and neck, pancreatic and brain. Its pipeline consists of RAD101, RAD102, RAD104, RAD105, RAD106, and RAD201 among others.

RAD Intrinsic Value
Not Available

See Also

What is Radiopharm Theranostics Ltd's Revenue?
Revenue
3.6m AUD

Based on the financial report for Jun 30, 2025, Radiopharm Theranostics Ltd's Revenue amounts to 3.6m AUD.

What is Radiopharm Theranostics Ltd's Revenue growth rate?
Revenue CAGR 1Y
1 114%

Over the last year, the Revenue growth was 1 114%.

Back to Top